Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 550.02%.
The current valuation score of Rallybio Corp is 8.09. Its current P/E ratio is -12.41, which is -98.12% below the recent high of -0.23 and -21.93% above the recent low of -15.13.
The current earnings forecast score of Rallybio Corp is 6.00. The average price target is 8.00, with a high of 8.00 and a low of 8.00.
The current price momentum score of Rallybio Corp is 2.06. Currently, the stock price is trading between the resistance level at 17.30 and the support level at 16.49, making it suitable for range-bound swing trading.
The latest institutional shareholding proportion is 65.82%, representing a quarter-over-quarter decrease of 1.97%.
The current risk assessment score of Rallybio Corp is 5.15. The company's beta value is -0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.